Medtronic Receives CE Mark for Valiant With Xcelerant System

Medtronic has obtained CE Mark approval on its Valiant Thoracic Stent Graft with Xcelerant Delivery System for commercial release in Europe.

The Valiant system is a next-generation stent graft that is more conformable than earlier generation devices, and the Xcelerant delivery system enables precise transluminal deployment of the stent graft. It also offers more size and end configuration options, giving physicians a greater opportunity to match the graft to the anatomy of the patient.

The Valiant thoracic system also will offer covered graft lengths of up to 20 cm for maximum lesion coverage and the use of fewer graft segments to complete procedures. Medtronic's commercialization of the Valiant system outside the U.S. will be phased in over the spring and summer.